BR112022010754A2 - Análogos de rapamicina e usos dos mesmos - Google Patents
Análogos de rapamicina e usos dos mesmosInfo
- Publication number
- BR112022010754A2 BR112022010754A2 BR112022010754A BR112022010754A BR112022010754A2 BR 112022010754 A2 BR112022010754 A2 BR 112022010754A2 BR 112022010754 A BR112022010754 A BR 112022010754A BR 112022010754 A BR112022010754 A BR 112022010754A BR 112022010754 A2 BR112022010754 A2 BR 112022010754A2
- Authority
- BR
- Brazil
- Prior art keywords
- rapamicin
- analogs
- compounds
- present
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962944166P | 2019-12-05 | 2019-12-05 | |
| PCT/US2020/063351 WO2021113665A1 (en) | 2019-12-05 | 2020-12-04 | Rapamycin analogs and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022010754A2 true BR112022010754A2 (pt) | 2022-08-23 |
Family
ID=76222025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022010754A BR112022010754A2 (pt) | 2019-12-05 | 2020-12-04 | Análogos de rapamicina e usos dos mesmos |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11819476B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4069223A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023506410A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220128345A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115209897A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020397938A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022010754A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3163680A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL293549A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022006807A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202134234A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021113665A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3127448C (en) | 2019-01-22 | 2024-06-04 | Aeovian Pharmaceuticals, Inc. | Mtorc modulators and uses thereof |
| EP4069223A4 (en) * | 2019-12-05 | 2023-12-20 | Janssen Pharmaceutica NV | RAPAMYCIN ANALOGS AND THEIR USES |
| CN115776907B (zh) | 2020-03-27 | 2025-02-25 | 艾奥维安制药公司 | Mtorc1调节剂及其用途 |
| CN121426814A (zh) * | 2020-07-21 | 2026-01-30 | 艾奥维安制药公司 | Mtorc1调节剂及其用途 |
| JP2024503898A (ja) * | 2021-01-22 | 2024-01-29 | ヤンセン ファーマシューティカ エヌ.ベー. | ラパマイシン類似体及びその使用 |
| CN116917294A (zh) * | 2021-01-22 | 2023-10-20 | 詹森药业有限公司 | 雷帕霉素类似物及其用途 |
| CN114539203A (zh) * | 2022-03-10 | 2022-05-27 | 李科 | 一种低成本碳酸亚乙烯酯的合成方法 |
| US20250334588A1 (en) * | 2022-04-09 | 2025-10-30 | The Brigham And Women's Hospital, Inc. | Treating tuberous sclerosis complex-associated diseases |
| CN115097046B (zh) * | 2022-07-07 | 2023-09-26 | 国药集团川抗制药有限公司 | 一种分离雷帕霉素及其杂质的方法 |
| CN116642992A (zh) * | 2023-04-27 | 2023-08-25 | 河北省药品医疗器械检验研究院(河北省化妆品检验研究中心) | 一种人体血浆抗肝癌哺乳动物雷帕霉素靶蛋白抑制剂串联质谱检测试剂盒 |
| GB202415232D0 (en) | 2024-10-16 | 2024-11-27 | Nacamed As | Composition |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA935112B (en) * | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
| US5260300A (en) | 1992-11-19 | 1993-11-09 | American Home Products Corporation | Rapamycin carbonate esters as immuno-suppressant agents |
| WO1994025072A1 (en) | 1993-04-23 | 1994-11-10 | American Home Products Corporation | Rapamycin conjugates and antibodies |
| EP0729471A1 (en) | 1993-11-19 | 1996-09-04 | Abbott Laboratories | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
| BR9408323A (pt) | 1993-12-17 | 1997-08-19 | Sandoz Ag | Derivados de rapamicina |
| US5362735A (en) | 1994-02-23 | 1994-11-08 | Smithkline Beecham Corporation | Rapamycin derivatives |
| US5639600A (en) | 1994-08-05 | 1997-06-17 | The Regents Of The University Of California | Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement |
| JP3934705B2 (ja) * | 1995-05-26 | 2007-06-20 | ノバルティス ファーマ株式会社 | サイクロデキストリン組成物 |
| KR19990022651A (ko) | 1995-06-07 | 1999-03-25 | 데이비드 엘. 버스테인 | 생물학적 사건에 대한 라파마이신 기재 조절방법 |
| DE69624921T2 (de) | 1995-06-09 | 2003-09-11 | Novartis Ag, Basel | Rapamycinderivate |
| WO1998002441A2 (en) * | 1996-07-12 | 1998-01-22 | Ariad Pharmaceuticals, Inc. | Non immunosuppressive antifungal rapalogs |
| CA2257803C (en) | 1996-07-12 | 2008-12-02 | Ariad Pharmaceuticals, Inc. | Non immunosuppressive antifungal rapalogs |
| CN1235608A (zh) | 1996-09-09 | 1999-11-17 | 美国家用产品公司 | 烷基化的雷帕霉素衍生物 |
| US5922730A (en) | 1996-09-09 | 1999-07-13 | American Home Products Corporation | Alkylated rapamycin derivatives |
| US6342507B1 (en) | 1997-09-05 | 2002-01-29 | Isotechnika, Inc. | Deuterated rapamycin compounds, method and uses thereof |
| US7087648B1 (en) | 1997-10-27 | 2006-08-08 | The Regents Of The University Of California | Methods for modulating macrophage proliferation using polyamine analogs |
| WO1999036553A2 (en) * | 1998-01-15 | 1999-07-22 | Ariad Gene Therapeutics, Inc. | Regulation of biological events using multimeric chimeric proteins |
| US7067526B1 (en) | 1999-08-24 | 2006-06-27 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
| IL147803A0 (en) | 1999-08-24 | 2002-08-14 | Ariad Gene Therapeutics Inc | 28-epirapalogs |
| TWI256395B (en) | 1999-09-29 | 2006-06-11 | Wyeth Corp | Regioselective synthesis of rapamycin derivatives |
| OA12118A (en) | 1999-12-10 | 2006-05-04 | Pfizer Prod Inc | PyrroloÄ2,3-dÜpyrimidine compounds. |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| KR100833371B1 (ko) | 2001-04-27 | 2008-05-28 | 젠야쿠코교가부시키가이샤 | 헤테로시클릭 화합물 및 이를 유효 성분으로 하는 항종양제 |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| US20040001878A1 (en) * | 2002-06-26 | 2004-01-01 | Deroyal Industries, Inc. | Infused wound care dressings |
| MXPA05001766A (es) | 2002-08-14 | 2005-08-19 | Atugen Ag | Uso de proteina quinasa n beta. |
| WO2004089925A1 (en) | 2003-04-03 | 2004-10-21 | Semafore Pharmaceuticals, Inc. | Pi-3 kinase inhibitor prodrugs |
| ES2382377T3 (es) | 2003-05-30 | 2012-06-07 | Gemin X Pharmaceuticals Canada Inc. | Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer |
| WO2005007623A2 (en) | 2003-07-03 | 2005-01-27 | The Trustees Of The University Of Pennsylvania | Inhibition of syk kinase expression |
| CA2531454C (en) * | 2003-07-08 | 2011-10-25 | Novartis Ag | Use of rapamycin and rapamycin derivatives for the treatment of bone loss |
| US7220755B2 (en) * | 2003-11-12 | 2007-05-22 | Biosensors International Group, Ltd. | 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same |
| LT2612862T (lt) | 2004-05-13 | 2017-01-25 | Icos Corporation | Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai |
| US20060189551A1 (en) * | 2004-10-04 | 2006-08-24 | Duke University | Combination therapies for fungal pathogens |
| US7449458B2 (en) | 2005-01-19 | 2008-11-11 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| GB0504994D0 (en) | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Novel compounds |
| US20060257337A1 (en) | 2005-04-28 | 2006-11-16 | David Sherris | Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis |
| ES2493466T3 (es) | 2005-05-12 | 2014-09-11 | Abbvie Bahamas Ltd. | Promotores de la apoptosis |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| HRP20140975T1 (hr) | 2005-10-07 | 2014-11-21 | Exelixis, Inc. | Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze |
| HRP20130902T1 (hr) | 2005-10-07 | 2013-11-08 | Exelixis Inc. | PIRIDOPIRIMIDINONSKI INHIBITORI PI3Kalfa |
| WO2007053452A1 (en) | 2005-11-01 | 2007-05-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| CA2630271C (en) | 2005-11-17 | 2014-04-08 | Osi Pharmaceuticals, Inc. | Fused bicyclic mtor inhibitors |
| HUE028588T2 (hu) | 2005-12-13 | 2016-12-28 | Incyte Holdings Corp | Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| US20070203168A1 (en) | 2006-02-28 | 2007-08-30 | Zhao Jonathon Z | Isomers of rapamycin and 42-Epi-rapamycin, methods of making and using the same |
| AR060391A1 (es) | 2006-04-11 | 2008-06-11 | Smithkline Beecham Corp | Compuestos de quinolin tiazolidinadiona, sustituidos con heterociclos, composiciones farmaceuticas que los contienen y usos para preparar medicamentos que inhiben la actividad de pi3 quinasas. |
| KR101533461B1 (ko) | 2006-04-26 | 2015-07-02 | 에프. 호프만-라 로슈 아게 | Pi3k저해제로 유용한 티에노[3,2-d]피리미딘 유도체 |
| US20080026591A1 (en) | 2006-07-28 | 2008-01-31 | Caracal, Inc. | Sintered metal components for crystal growth reactors |
| CA2663401C (en) | 2006-09-15 | 2011-07-12 | Pfizer Products Inc. | Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors |
| EP2529621B1 (en) | 2006-09-22 | 2016-10-05 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| PE20081679A1 (es) | 2006-12-07 | 2008-12-18 | Hoffmann La Roche | Compuestos del inhibidor de fosfoinositida 3-cinasa y metodos de uso |
| WO2008110491A2 (en) | 2007-03-09 | 2008-09-18 | University Of Basel | Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat |
| HUE029188T2 (en) | 2007-03-12 | 2017-03-28 | Ym Biosciences Australia Pty | Phenylamino-pyrimidine compounds and their use |
| US8394794B2 (en) | 2007-03-23 | 2013-03-12 | Regents Of The University Of Minnesota | Therapeutic compounds |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| MY165582A (en) | 2008-03-11 | 2018-04-05 | Incyte Holdings Corp | Azetidine and cyclobutane derivatives as jak inhibitors |
| US20090253733A1 (en) | 2008-04-02 | 2009-10-08 | Biointeractions, Ltd. | Rapamycin carbonate esters |
| MY155653A (en) | 2008-05-23 | 2015-11-13 | Wyeth Llc | Triazine compounds as p13 kinase and mtor inhibitors |
| WO2009153597A2 (en) | 2008-06-20 | 2009-12-23 | Astrazeneca Ab | Composition and process - 356 |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| US8110578B2 (en) | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| ES2345241B1 (es) | 2009-03-16 | 2011-09-08 | Lipopharma Therapeutics | Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos. |
| CA2756067A1 (en) | 2009-03-27 | 2010-09-30 | Pathway Therapeutics, Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
| DK2414362T3 (da) | 2009-04-03 | 2014-09-22 | Verastem Inc | Pyrimidinsubstituerede purinforbindelser som kinaseinhibitorer |
| WO2010118208A1 (en) | 2009-04-09 | 2010-10-14 | Exelixis, Inc. | Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer |
| US20130035336A1 (en) | 2010-04-13 | 2013-02-07 | Novartis Ag | Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor for treating cancer |
| US9062046B2 (en) | 2010-07-16 | 2015-06-23 | Piramal Enterprises Limited | Substituted imidazoquinoline derivatives as kinase inhibitors |
| JO3003B1 (ar) | 2011-01-14 | 2016-09-05 | Lilly Co Eli | مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor |
| US8808256B2 (en) | 2012-01-16 | 2014-08-19 | Johnson & Johnson Vision Care, Inc. | Eye drug delivery system |
| US9072678B2 (en) | 2013-03-14 | 2015-07-07 | Pathak Holdings Llc | Methods for local drug delivery by microinjection |
| WO2015051043A1 (en) | 2013-10-01 | 2015-04-09 | Amgen Inc. | Biaryl acyl-sulfonamide compounds as sodium channel inhibitors |
| DK3102576T3 (da) | 2014-02-03 | 2019-07-22 | Vitae Pharmaceuticals Llc | Dihydropyrrolopyridininhibitorer af ror-gamma |
| EP3193902A4 (en) | 2014-09-11 | 2018-03-28 | The Regents of The University of California | mTORC1 INHIBITORS |
| US20160279108A1 (en) | 2015-02-24 | 2016-09-29 | University Of Kansas | Targeted mtor inhibitors |
| US10683308B2 (en) * | 2015-09-11 | 2020-06-16 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| CA3061907A1 (en) | 2017-05-02 | 2018-11-08 | Revolution Medicines, Inc. | Rapamycin analogs as mtor inhibitors |
| UY37900A (es) | 2017-09-26 | 2019-04-30 | Novartis Ag | Nuevos derivados de rapamicina |
| US10980784B2 (en) * | 2018-06-15 | 2021-04-20 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| WO2020076738A2 (en) * | 2018-10-12 | 2020-04-16 | Bellicum Pharmaceuticals, Inc | Protein-binding compounds |
| LT3898637T (lt) | 2018-12-18 | 2025-03-10 | Novartis Ag | Rapamicino dariniai |
| CA3127448C (en) * | 2019-01-22 | 2024-06-04 | Aeovian Pharmaceuticals, Inc. | Mtorc modulators and uses thereof |
| KR20260115158A (ko) | 2019-03-26 | 2026-07-23 | 노파르티스 아게 | 이소티아졸리딘 1,1-디옥시드 및 1,4-부탄 술톤 함유 라파마이신 유도체 및 이의 용도 |
| EP4069223A4 (en) * | 2019-12-05 | 2023-12-20 | Janssen Pharmaceutica NV | RAPAMYCIN ANALOGS AND THEIR USES |
| CN115776907B (zh) | 2020-03-27 | 2025-02-25 | 艾奥维安制药公司 | Mtorc1调节剂及其用途 |
| CN121426814A (zh) | 2020-07-21 | 2026-01-30 | 艾奥维安制药公司 | Mtorc1调节剂及其用途 |
-
2020
- 2020-12-04 EP EP20895785.2A patent/EP4069223A4/en not_active Withdrawn
- 2020-12-04 TW TW109142952A patent/TW202134234A/zh unknown
- 2020-12-04 AU AU2020397938A patent/AU2020397938A1/en not_active Abandoned
- 2020-12-04 BR BR112022010754A patent/BR112022010754A2/pt not_active Application Discontinuation
- 2020-12-04 US US17/111,674 patent/US11819476B2/en active Active
- 2020-12-04 CA CA3163680A patent/CA3163680A1/en active Pending
- 2020-12-04 WO PCT/US2020/063351 patent/WO2021113665A1/en not_active Ceased
- 2020-12-04 CN CN202080095831.5A patent/CN115209897A/zh active Pending
- 2020-12-04 MX MX2022006807A patent/MX2022006807A/es unknown
- 2020-12-04 IL IL293549A patent/IL293549A/en unknown
- 2020-12-04 KR KR1020227022865A patent/KR20220128345A/ko not_active Withdrawn
- 2020-12-04 JP JP2022534146A patent/JP2023506410A/ja active Pending
-
2023
- 2023-11-01 US US18/499,580 patent/US20240139164A1/en not_active Abandoned
- 2023-11-01 US US18/499,511 patent/US20240131012A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022006807A (es) | 2022-09-12 |
| AU2020397938A1 (en) | 2022-06-23 |
| EP4069223A4 (en) | 2023-12-20 |
| US11819476B2 (en) | 2023-11-21 |
| US20210186935A1 (en) | 2021-06-24 |
| KR20220128345A (ko) | 2022-09-20 |
| JP2023506410A (ja) | 2023-02-16 |
| TW202134234A (zh) | 2021-09-16 |
| IL293549A (en) | 2022-08-01 |
| US20240131012A1 (en) | 2024-04-25 |
| CN115209897A (zh) | 2022-10-18 |
| EP4069223A1 (en) | 2022-10-12 |
| CA3163680A1 (en) | 2021-06-10 |
| US20240139164A1 (en) | 2024-05-02 |
| WO2021113665A1 (en) | 2021-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021022457A2 (pt) | Inibidores de fgfr e métodos de uso dos mesmos | |
| ECSP22052564A (es) | Tetrahidrofuranos sustituidos como moduladores de canales de sodio | |
| CL2022000751A1 (es) | Inhibidores de la fosfatasa shp2 y métodos para su uso (divisional de la solicitud no. 202002419) | |
| MX2020010999A (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos. | |
| ECSP19070369A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP19083621A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP19070413A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP19083640A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| MX2022006807A (es) | Análogos de rapamicina y usos de estos. | |
| BR112018073663A2 (pt) | moduladores de receptores nmda spiro-lactâmicos e seus usos | |
| CL2014003181A1 (es) | Compuestos derivados de benzamidas n- sustituidas o piridinamidas n-sustituidas; composicion farmaceutica que los comprende; metodo de tratamiento; y su uso para el tratamiento de enfermedades o trastornos seleccionados de dolor, depresion y enfermedades cardiovasculares, respiratorias o psiquiatricas o combinaciones de estas. | |
| CO2022004698A2 (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 | |
| ECSP18073293A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| BR112015018092A2 (pt) | moduladores de receptor de nmda de espiro-lactama e usos dos mesmos | |
| BR112019001768A2 (pt) | moduladores do receptor de spiro-lactamas nmda e usos dos mesmos | |
| BR112015018094A2 (pt) | moduladores de receptor nmda de espiro-lactama e usos dos mesmos | |
| BR112015018087A2 (pt) | moduladores de receptor nmda de espiro-lactama e usos dos mesmos | |
| BR112015018089A2 (pt) | moduladores de receptor de nmda de espiro-lactama e usos dos mesmos | |
| BR112021011325A2 (pt) | Derivados de rapamicina | |
| CR20180496A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| MX2021012248A (es) | Polimorfos de voruciclib y metodos de elaboracion y uso de los mismos. | |
| AR080871A1 (es) | Tieno[3,2-b]piridinas sustituidas como inhibidores de la actividad de la proteina tirosina quinasa | |
| MX2024008372A (es) | Compuestos organicos deuterados y usos de los mismos | |
| CO2021008962A2 (es) | Derivados activos de éster de testosterona, composiciones y usos de los mismos | |
| BR112018073419A2 (pt) | combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: ANAKURIA THERAPEUTICS, INC. (US) |
|
| B25A | Requested transfer of rights approved |
Owner name: JANSSEN PHARMACEUTICA NV (BE) |
|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |